Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 13/20 | 0.69 |
| ▸ | MAOA | P21397 | 6/20 | 0.69 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.69 |
| ▸ | SDHA | P31040 | 2/20 | 0.69 |
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
| ▸ | CALML3 | P27482 | 1/20 | 0.69 |
| ▸ | F10 | P00742 | 4/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1336215 | 1.00 | MAOB (0.69) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL29439547 | 1.00 | MAOB (0.69) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL5513933 | 1.00 | MAOB (0.69) | MAOBMAOAPTGS1SDHALMNA | |
| Acetic Acid SCHEMBL1338391 | 0.94 | MAOB (0.74) | MAOBMAOAPTGS1SDHALMNA | |
| Acetic Acid SCHEMBL1338393 | 0.94 | MAOB (0.74) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL3523989 | 0.91 | F10 (0.59) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL3523994 | 0.91 | F10 (0.59) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL3525075 | 0.89 | F10 (0.58) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL12176864 | 0.89 | MAOB (0.70) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL13404010 | 0.89 | F10 (0.58) | MAOBMAOAPTGS1SDHALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 337 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114505036-A | Method and equipment for preparing linezolid | 程竹隐 | 2022-05-17 | — | — | CN | claimed |
| EP-2902386-B1 | A crystalline form of linezolid | SYMED LABS LTD (IN) | 2020-04-08 | — | — | EP | claimed |
| CN-110934880-A | Compositions containing mixtures of phenyl oxazolidinone derivatives and uses thereof | 黄泳华 | 2020-03-31 | — | — | CN | claimed |
| US-9586913-B2 | Processes for the preparation of linezolid using novel intermediates | SYMED LABS LIMITED (IN) | 2017-03-07 | — | — | US | claimed |
| WO-2016113751-A1 | PROCESS FOR PREPARING CRYSTALLINE LINEZOLID FORM-III | NOSCH LABS PRIVATE LIMITED (IN) | 2016-07-21 | — | — | WO | claimed |
| US-9376407-B2 | Process for preparation of Linezolid and its novel intermediates | LEE PHARMA LIMITED (IN) | 2016-06-28 | — | — | US | claimed |
| US-20160102064-A1 | IMPROVED PROCESSES FOR THE PREPARATION OF LINEZOLID USING NOVEL INTERMEDIATES | SYMED LABS LIMITED (IN) | 2016-04-14 | — | — | US | claimed |
| EP-2989097-A1 | IMPROVED PROCESSES FOR THE PREPARATION OF LINEZOLID USING NOVEL INTERMEDIATES | Symed Labs Limited (IN) | 2016-03-02 | — | — | EP | claimed |
| EP-2595968-B1 | NOVEL PROCESS FOR PREPARATION OF LINEZOLID AND ITS NOVEL INTERMEDIATES | LEE PHARMA LTD (IN) | 2015-09-09 | — | — | EP | claimed |
| EP-2902386-A1 | A crystalline form of linezolid | Symed Labs Limited (IN) | 2015-08-05 | — | — | EP | claimed |
| EP-1861383-A2 | ISOLATED BIS-LINEZOLID, PREPARATION THEREOF, AND ITS USE AS A REFERENCE STANDARD | Teva Pharmaceutical Industries Ltd (IL) | 2007-12-05 | — | — | EP | claimed |
| EP-1737850-B1 | A NOVEL PROCESS FOR THE PREPARATION OF LINEZOLID AND RELATED COMPOUNDS | SYMED LABS LTD (IN) | 2007-10-03 | — | — | EP | claimed |
| EP-1768967-A1 | NOVEL INTERMEDIATES FOR LINEZOLID AND RELATED COMPOUNDS | Symed Labs Limited (IN) | 2007-04-04 | — | — | EP | claimed |
| US-20070032472-A1 | Novel process for the preparation of linezolid and related compounds | SYMED LABS LIMITED (IN) | 2007-02-08 | — | — | US | claimed |
| US-20060252932-A1 | Isolated bis-linezolid, preparation thereof, and its use as a reference standard | ENTIRE INTEREST | 2006-11-09 | — | — | US | claimed |
| WO-2006091848-A9 | ISOLATED BIS-LINEZOLID, PREPARATION THEREOF, AND ITS USE AS A REFERENCE STANDARD | TEVA PHARMA (IL) | 2006-11-09 | — | — | WO | claimed |
| US-20060247435-A1 | Novel intermediates for linezolid and related compounds | HETERO USA, INC. (US) | 2006-11-02 | — | — | US | claimed |
| WO-2006091848-A2 | ISOLATED BIS-LINEZOLID, PREPARATION THEREOF, AND ITS USE AS A REFERENCE STANDARD | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2006-08-31 | — | — | WO | claimed |
| US-20060128703-A1 | Novel crystalline form of linezolid | SYMED LABS LIMITED (IN) | 2006-06-15 | — | — | US | claimed |
| WO-2006008754-A1 | NOVEL INTERMEDIATES FOR LINEZOLID AND RELATED COMPOUNDS | SYMED LABS LIMITED (IN) | 2006-01-26 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160102064-A1 | IMPROVED PROCESSES FOR THE PREPARATION OF LINEZOLID USING NOVEL INTERMEDIATES | CYP3A5, SBDS, MLYCD | MAOB 951/4885MAOA 522/4885PTGS1 2907/4885 |
| US-20060128703-A1 | Novel crystalline form of linezolid | PYCARD, NLRP3, NLRP1 | MAOB 3168/4885MAOA 2402/4885PTGS1 4691/4885 |
| US-20060252932-A1 | Isolated bis-linezolid, preparation thereof, and its use as a reference standard | FHIT, CYP2C9, CYP2C19 | MAOB 2182/4885MAOA 2591/4885PTGS1 4246/4885 |
| US-20070032472-A1 | Novel process for the preparation of linezolid and related compounds | EED, EML4, KDM5D | MAOB 946/4885MAOA 999/4885PTGS1 4504/4885 |
| US-20060247435-A1 | Novel intermediates for linezolid and related compounds | HPD, PTMS, HDAC5 | MAOB 1181/4885MAOA 1155/4885PTGS1 4327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.